安博维联合苯磺酸氨氯地平对肾性高血压患者尿蛋白和血肌酐及血尿酸水平的影响

Effects of Ambovir combined with amlodipine besylate on urinary protein,serum creatinine,and serum uric acid levels in patients with renal hypertension

目的探讨安博维联合苯磺酸氨氯地平对肾性高血压患者尿蛋白、血肌酐及血尿酸水平的影响。方法选取2017年1月至2019年8月本院收治的肾性高血压患者82例,应用双色球分组法分为对照组与研究组。对照组给予苯磺酸氨氯地平治疗,研究组给予安博维联合苯磺酸氨氯地平治疗。对比两组尿蛋白、血肌酐、血尿酸水平,两组临床疗效以及用药不良反应状况。结果治疗干预前,对照组血肌酐和血尿酸、尿蛋白水平分别为(348.06±68.15)μmol/L、(453.45±20.25)μmol/L、(1.78±0.56)g/L,研究组上述指标水平分别为(348.08±68.24)μmol/L、(452.05±20.47)μmol/L、(1.79±0.55)g/L,差异无统计学意义(P>0.05);治疗后两组上述指标水平均得到改善,对照组指标分别为(321.25±40.26)μmol/L、(415.13±18.25)μmol/L、(1.64±0.51)g/L,治疗后研究组指标水平分别为(271.24±29.45)μmol/L、(363.15±12.34)μmol/L、(1.44±0.32)g/L,研究组更理想,差异有统计学意义(P<0.05);对照组嗜睡疲劳、头晕头痛、恶心、体位性低血压、潮红等不良反应的总发生率为31.7%,研究组为29.3%,两组比较差异无统计学意义(P>0.05);研究组临床治疗显效率优于对照组(73.2%比48.8%,P<0.05)。结论将安博维与苯磺酸氨氯地平联合治疗方案应用至肾性高血压的临床治疗中,可提升临床疗效,降低患者尿蛋白、血肌酐和血尿酸水平,不会增加用药不良反应,可考虑应用普及。

Objective To investigate the effects of Ambovir combined with amlodipine besylate on urine protein,serum creatinine,and serum uric acid levels in patients with renal hypertension.Methods Eighty-two patients with renal hypertension admitted to our hospital from January 2017 to August 2019 were divided into two groups with the two-color ball grouping method:control group and study group.The control group was treated with amlodipine besylate,and the study group was treated with Ambovir combined with amlodipine besylate.The urinary protein,serum creatinine,and serum uric acid levels were compared between the two groups.The clinical efficacy and the adverse drug reactions of the two groups were compared.Results Before treatment,there were no statistically significant differences in,serum creatinine,serum uric acid,and urine protein levels between the control group and the study group[(348.06±68.15)μmol/L,(453.45±20.25)μmol/L,(1.78±0.56)g/L;(348.08±68.24)μmol/L,(452.05±20.47)μmol/L,(1.79±0.55)g/L](P>0.05).The levels of the above indicators improved after treatment in the control group and the study group[(321.25±40.26)μmol/L,(415.13±18.25)μmol/L,(1.64±0.51)g/L;(271.24±29.45)μmol/L,(363.15±12.34)μmol/L,(1.44±0.32)g/L],those in the study group were more ideal(P<0.05).The total incidence of adverse reactions such as drowsiness and fatigue,dizziness and headache,nausea,orthostatic hypotension,flushing was 31.7%in the control group,29.3%in the study group,there was no statistically significant difference between the two groups(P>0.05).The clinical effective rate was 73.2%in the study group and 48.8%in the control group,the study group was superior to the control group(P<0.05).Conclusion The combination of Ambovir and amlodipine besylate can improve clinical efficacy in the clinical treatment of renal hypertension,reduce urine protein,serum creatinine,and blood uric acid levels,and will not increase adverse drug reactions,which is worthy of clinical application.